The first generation of HDAC inhibitors, such as Vorinostat and Romidepsin, have been approved for cutaneous T cell lymphoma (CTCL) therapy [6]. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.